Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Electromed (ELMD) has delivered strong revenue growth and margin improvement, but faces a highly competitive, fragmented market for its SmartVest product. ELMD lacks a durable moat, with rivals like Tactile Medical and Baxter showing stronger brand recognition, technological advantages, and higher recent growth rates. Scientific evidence questions the comparative efficacy of HFCWO versus alternative airway clearance therapies, undermining the long-term growth thesis for SmartVest.

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.

Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.

Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript

Electromed, Inc. (ELMD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter.